HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating for Olema Pharmaceuticals (NASDAQ:OLMA) and maintained a price target of $30.
October 24, 2024 | 9:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Olema Pharmaceuticals, maintaining a $30 price target, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst suggests positive sentiment and potential upside for Olema Pharmaceuticals. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100